Efficacy and Safety of Different Doses of Lidocaine Intravenous Infusion on Postherpetic Neuralgia and Its Effects on Dosage of Analgesic Drugs

WANG Shanshan; LIU Yong; ZENG Xin

doi:10.14009/j.issn.1672-2124.2020.07.001

您当前的位置：

首页 >

文章列表页 >

Efficacy and Safety of Different Doses of Lidocaine Intravenous Infusion on Postherpetic Neuralgia and Its Effects on Dosage of Analgesic Drugs

更新时间：2022-10-08

- Efficacy and Safety of Different Doses of Lidocaine Intravenous Infusion on Postherpetic Neuralgia and Its Effects on Dosage of Analgesic Drugs
- Vol. 20, Issue 7, Pages: 769-772(2020)
- 作者机构：
  
  1. 陆军军医大学第二附属医院疼痛康复科
  2. 重庆市药品技术审评认证中心
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.07.001
  CLC： R971
- Published：2020，
扫描看全文
[1]王珊珊,刘勇,曾昕.不同剂量利多卡因静脉滴注治疗带状疱疹后神经痛的疗效和安全性及对镇痛药用量的影响[J].中国医院用药评价与分析,2020,20(07):769-772+777.

WANG Shanshan, LIU Yong, ZENG Xin. Efficacy and Safety of Different Doses of Lidocaine Intravenous Infusion on Postherpetic Neuralgia and Its Effects on Dosage of Analgesic Drugs. [J]. 20(7):769-772(2020)
[1]王珊珊,刘勇,曾昕.不同剂量利多卡因静脉滴注治疗带状疱疹后神经痛的疗效和安全性及对镇痛药用量的影响[J].中国医院用药评价与分析,2020,20(07):769-772+777. DOI： 10.14009/j.issn.1672-2124.2020.07.001.

WANG Shanshan, LIU Yong, ZENG Xin. Efficacy and Safety of Different Doses of Lidocaine Intravenous Infusion on Postherpetic Neuralgia and Its Effects on Dosage of Analgesic Drugs. [J]. 20(7):769-772(2020) DOI： 10.14009/j.issn.1672-2124.2020.07.001.

摘要

目的:探讨不同剂量利多卡因静脉滴注治疗带状疱疹后神经痛的临床疗效、安全性及对镇痛药用量的影响。方法:选取2018年1月至2019年6月陆军军医大学第二附属医院疼痛科确诊收治的带状疱疹神经痛患者为研究对象

共180例

按照随机数字表法分为常规组、利多卡因A组和利多卡因B组

每组60例。常规组患者给予常规药物治疗

利多卡因A组患者在常规药物治疗的基础上给予静脉滴注0.1%利多卡因100 ml/d

利多卡因B组患者在常规药物治疗的基础上给予静脉滴注0.1%利多卡因200 ml/d。观察两组患者入院时（D

）、治疗第1日（D

）、治疗第3日（D

）及治疗第7日（D

）的疼痛情况[视觉模拟评分（visual analogue scale

VAS）]、睡眠情况[睡眠质量评分（quality of sleep

QS）]

、负性情绪情况[汉密尔顿焦虑量表（Hamilton anxiety scale

HAMA）和汉密尔顿抑郁量表（Hamilton depression scale

HAMD）]、镇痛药使用情况及不良反应发生情况。结果:利多卡因A组、利多卡因B组患者在D

、D

及D

的VAS评分和QS评分明显低于常规组

差异均有统计学意义（P

0.05）

且利多卡因B组患者D

的VAS评分和D

、D

及D

的QS评分明显低于利多卡因A组

差异均有统计学意义（P

0.05）。利多卡因A组、利多卡因B组患者在D

、D

及D

的HAMA评分和D

、D

的HAMD评分明显低于常规组

差异均有统计学意义（P

0.05）

且利多卡因B组患者D

的HAMA评分和HAMD评分明显低于利多卡因A组

差异均有统计学意义（P

0.05）。利多卡因A组、利多卡因B组患者在D

、D

的氨酚羟考酮用量和D

的曲马多用量明显低于常规组

差异均有统计学意义（P

0.05）;利多卡因B组患者D

的曲马多用量明显低于常规组

差异有统计学意义（P

0.05）;利多卡因B组患者D

、D

的氨酚羟考酮用量和D

的曲马多用量明显低于利多卡因A组

差异均有统计学意义（P

0.05）。三组患者均未因严重不良反应无法完成治疗

三组间不良反应总发生率的差异均无统计学意义（P

0.05）。结论:利多卡因治疗带状疱疹后神经痛具有良好的临床疗效

可减少曲马多等镇痛药的用量

不增加药品不良反应

安全性好;且利多卡因200 ml/d的效果更优。

Abstract

OBJECTIVE: To probe into the clinical efficacy and safety of different doses of lidocaine intravenous infusion on postherpetic neuralgia and its effects on dosage of analgesic drugs.METHODS: Totally 180 patients with postherpetic neuralgia diagnosed in the pain department of the Second Affiliated Hospital of Army Military Medical University from Jan.2018 to Jun.2019 were selected to be divided into the conventional group

the lidocaine group A and the lidocaine group B via the random number table

with 60 cases in each group.The conventional group were treated with conventional drugs

the lidocaine group A were given intravenous infusion of 0.1% lidocaine 100 ml/d on the basis of conventional drugs

and the lidocaine B group received intravenous infusion of 0.1% lidocaine 200 ml/d on the basis of conventional drugs.Pain status [visual analogue scale（ VAS） ]

sleep status [quality of sleep score（ QS） ]

negative mood status [Hamilton anxiety scale（ HAMA） and Hamilton depression scale（ HAMD） ]

the application of analgesics and adverse drug reactions were observed in admission（ D

）

the treatment day 1（ D

）

the treatment day 3（ D

） and the treatment day 7（ D

）.RESULTS: The VAS score and QS score of lidocaine group A and lidocaine group B were significantly lower than those of the conventional group in D

and D

the difference was statistically significant（ P

0.05）.The VAS score in D

and QS score in D

and D

of lidocaine group B were significantly lower than those of lidocaine group A

the difference was statistically significant（ P

0.05）.The HAMA score in D

and D

and HAMD score in D

and D

of lidocaine group A and lidocaine group B were significantly lower than those of the conventional group（ P

0.05）

and the HAMA score and HAMD score in D

of lidocaine group B were significantly lower than those of lidocaine group A

with statistically significant differences（ P

0.05）.The doses of oxycodone and acetaminophen in D

and D

and tramadol in D

in lidocaine group A and lidocaine group B in D

and D

were significantly lower than those in the conventional group

the differences were statistically significant（ P

0.05）; the doses of tramadol in D

in lidocaine group B were significantly lower than that in the conventional group

with statistically significant difference（ P

0.05）

and the doses of oxycodone and acetaminophen in D

and D

and tramadol in D

in lidocaine group B were significantly lower than those in lidocaine group A

with statistically significant differences（ P

0.05）.None of the patients in three groups could not complete the treatment due to severe adverse drug reactions

and the difference in the total incidence of adverse drug reactions among three groups was not statistically significant（ P

0.05）.CONCLUSIONS: Lidocaine has significant clinical efficacy in the treatment of postherpetic neuralgia

and can reduce the dosage of tramadol and other analgesic drugs

without increasing the adverse drug reactions and the safety is higher.Moreover

the effect of 200 ml/d lidocaine is better.

关键词

带状疱疹后神经痛疼痛利多卡因安全性

Keywords

Postherpetic neuralgiaPainLidocaineSafety

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Efficacy and Safety of Sacubitril Valsartan in the Treatment of Hypertension

Efficacy and Safety of Compound Lactobacillus Acidophilus Combined with Different Antispasmodic Agents in the Treatment of Diarrhea Irritable Bowel Syndrome: A Systematic Review

Systematic Review of Efficacy and Safety of Cefoperazone Sulbactam in Obstetrics and Gynecology Infections

Effects of the Internet of Things Health Management Model on Medication Compliance and Safety in Elderly Patients with Multiple Medications

Efficacy and Safety of Apatinib Mesylate Combined with Etoposide in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Related Author

CHEN Can

LI Xiaoye

TIAN Dan

LI Jing

LYU Qianzhou

LI Xiaoyu

LI Daixiao

LI Huibo

Related Institution

Dept.of Pharmacy, Zhongshan Hospital, Fudan University

Dept.of Pharmacy, Children’s Hospital Affiliated to Zhengzhou University

Dept.of Pharmacy, the Affiliated Hospital of Chengde Medical College

Dept.of Pharmacy, Peking University Third Hospital

Institute for Drug Evaluation, Peking University Health Science Center

⁰